BioNTech SE (BNTX) Stock Valuation — DCF Analysis
Biotechnology · NASDAQ
Current Price
$90.54
Intrinsic Value
$78.44
-15.4% margin of safety
COMPETITIVE MOAT
↑mRNA Technology Leadership
BioNTech's pioneering mRNA platform offers a significant technological advantage. This expertise allows for rapid development and adaptation of novel therapeutics and vaccines.
↑Strategic Partnerships
Collaborations with major pharmaceutical companies like Bristol Myers Squibb expand BioNTech's reach and validate its pipeline. These partnerships accelerate clinical trials and market access.
↑Oncology Pipeline Depth
A robust and diverse oncology pipeline, including promising bispecific candidates like pumitamig, demonstrates BioNTech's commitment to a critical therapeutic area. This diversification reduces reliance on single products.
INVESTMENT RISKS
↓Regulatory Hurdles
The biotechnology industry faces stringent regulatory approval processes. Delays or rejections for key drug candidates can significantly impact revenue and growth prospects.
↓Competition in Oncology
The oncology market is highly competitive with numerous established and emerging players. BioNTech's pipeline faces pressure from existing treatments and new entrants.
↓Dependence on Key Partnerships
While partnerships are a strength, over-reliance on a few major collaborators creates risk. Changes in partner strategies or financial health could disrupt development and commercialization.
Base case
BNTX base case valuation
A base case discounted cash flow model for BNTX estimates an intrinsic value of about $78.44 per share, against a current price of $90.54. The model assumes 3.1% annual free cash flow growth, a 10.0% discount rate, and a 29x exit multiple.
Intrinsic Value
$78.44
Margin of safety
-15.4%
Expected annual return
-2.8%
Base case assumptions: 3.1% annual growth, 10.0% discount rate, 29x exit multiple, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the BNTX valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for BioNTech SE respond.
Open DCF Calculator for BNTXCompany Overview
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Financial Metrics — BNTX Stock Valuation Data
Revenue/Share (TTM)
$11.04
FCF/Share (TTM)
$2.69
ROIC (TTM)
-7.5%
ROE (TTM)
-6.7%
P/FCF
29.0x
EV/EBITDA
-14.5x
FCF Yield
3.44%
Debt/Equity
0.02x
Based on trailing twelve-month data, BNTX shows a free cash flow per share of $2.69 and a ROIC of -7.5%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 29.0x and FCF yield of 3.44% are important context metrics when evaluating BNTX's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of BNTX?
BioNTech SE currently generates $2.69 in free cash flow per share. At the current price of $90.54, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is BNTX undervalued?
BNTX trades at a P/FCF ratio of 29.0x with a free cash flow yield of 3.44%. This P/FCF is in a moderate range. However, whether BNTX is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value BNTX stock using DCF?
To perform a DCF valuation on BioNTech SE: (1) Start with the trailing free cash flow per share ($2.69) as the base, (2) project future FCF growth over 5-10 years based on Biotechnology industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting BNTX's risk profile — with a debt-to-equity of 0.02x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to BNTX?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For BioNTech SE, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Biotechnology trends, then discounting those amounts to today's dollars. BNTX's ROIC of -7.5% suggests the company may face challenges generating returns above its cost of capital.
How does WACC affect BNTX stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For BNTX, with a debt-to-equity ratio of 0.02x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of -14.5x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See BNTX PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value BNTX with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.